Search research articles
Contact Us
Filters
Showing results (21-30 of 112) with videos related to
Page
of 12
Sort By:
Sociology of Health & Illness
|
February 15, 2011
Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation
Courtney Davis, John Abraham
Social Science & Medicine (1982)
|
May 27, 2003
Reshaping the carcinogenic risk assessment of medicines: international harmonisation for drug safety, industry/regulator efficiency or both?
John Abraham, Tim Reed
Social History of Medicine : the Journal of the Society for the Social History of Medicine
|
December 13, 2006
Testing times: the emergence of the practolol disaster and its challenge to British drug regulation in the modern period
John Abraham, Courtney Davis
Social Science & Medicine (1982)
|
April 9, 2011
The socio-political roots of pharmaceutical uncertainty in the evaluation of 'innovative' diabetes drugs in the European Union and the US
Courtney Davis, John Abraham
BMJ (Clinical Research Ed.)
|
February 8, 2013
Is there a cure for corporate crime in the drug industry?
Courtney Davis, John Abraham
Social Science & Medicine (1982)
|
May 4, 2020
International and temporal comparative analysis of UK and US drug safety regulation in changing political contexts
John Abraham, Courtney Davis
Annals of Biomedical Engineering
|
October 16, 2007
A simulation of gas-based, endometrial-ablation therapy
Ephraim Sparrow, John Abraham
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics
|
February 7, 2007
Dissipative-particle-dynamics model for two-phase flows
Anupam Tiwari, John Abraham
Social Science & Medicine (1982)
|
December 7, 2021
Corrigendum to "International and temporal comparative analysis of UK and US drug safety regulation in changing political contexts" [Soc. Sci. Med. 255 (2020) 113005]
John Abraham, Courtney Davis
Social Science & Medicine (1982)
|
July 13, 2012
Science, politics, and health in the brave new world of pharmaceutical carcinogenic risk assessment: technical progress or cycle of regulatory capture?
John Abraham, Rachel Ballinger
Page
of 12
Search research articles
Search
Showing results (21-30 of 112) with videos related to
Sort By:
Page
of 12
Sociology of Health & Illness
|
February 15, 2011
Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation
Courtney Davis, John Abraham
Social Science & Medicine (1982)
|
May 27, 2003
Reshaping the carcinogenic risk assessment of medicines: international harmonisation for drug safety, industry/regulator efficiency or both?
John Abraham, Tim Reed
Social History of Medicine : the Journal of the Society for the Social History of Medicine
|
December 13, 2006
Testing times: the emergence of the practolol disaster and its challenge to British drug regulation in the modern period
John Abraham, Courtney Davis
Social Science & Medicine (1982)
|
April 9, 2011
The socio-political roots of pharmaceutical uncertainty in the evaluation of 'innovative' diabetes drugs in the European Union and the US
Courtney Davis, John Abraham
BMJ (Clinical Research Ed.)
|
February 8, 2013
Is there a cure for corporate crime in the drug industry?
Courtney Davis, John Abraham
Social Science & Medicine (1982)
|
May 4, 2020
International and temporal comparative analysis of UK and US drug safety regulation in changing political contexts
John Abraham, Courtney Davis
Annals of Biomedical Engineering
|
October 16, 2007
A simulation of gas-based, endometrial-ablation therapy
Ephraim Sparrow, John Abraham
Physical Review. E, Statistical, Nonlinear, and Soft Matter Physics
|
February 7, 2007
Dissipative-particle-dynamics model for two-phase flows
Anupam Tiwari, John Abraham
Social Science & Medicine (1982)
|
December 7, 2021
Corrigendum to "International and temporal comparative analysis of UK and US drug safety regulation in changing political contexts" [Soc. Sci. Med. 255 (2020) 113005]
John Abraham, Courtney Davis
Social Science & Medicine (1982)
|
July 13, 2012
Science, politics, and health in the brave new world of pharmaceutical carcinogenic risk assessment: technical progress or cycle of regulatory capture?
John Abraham, Rachel Ballinger
Page
of 12